Kidney cancer (also known as renal cell carcinoma [RCC]) is diagnosed in 36,000 patients and is the cause of death of 11-13,000 individuals yearly in the US;unfortunately (and for unknown reasons), the incidence of this disease is increasing in all groups. One-third of cases, many of whom are asymptomatic, are metastatic at diagnosis and there is currently no available biofluid diagnostic test or adequate treatment once diagnosed. Given the relationship of the kidney to the urine, RCC is ideally suited for identification of urinary markers. In this revised proposal, we will exploit the new science of metabolomics to discover a pattern of urinary metabolites which serve as biomarkers for RCC in patients who are at high risk for this disease. We will support our biomarkers discovery by using pathway and network analysis to confirm which metabolic pathways go awry in this disease, using RCC tissues and cell lines. Finally, we will test our biomarkers in new samples from both RCC non-RCC patients, including as controls patients with non-malignant renal disease as well as patients who have non-renal cancers. For this revision, we have improved the proposal by adding all of the requested preliminary data. We have also submitted two publications related to RCC metabolomics as well as proteomics. Our proposal is extraordinary in that we have assembled a unique cadre of collaborators: a cell biologist who is also a clinician- scientist nephrologist (Dr. Weiss), a proteomics and genomics expert (Dr. Perroud), four metabolomics experts (Drs Fiehn, Hammock, Michelmore, and Grant), two biostatisticians (Drs. Kim and Rocke), two oncologic pathologists (Drs. Grizzle and Borowsky), and two urologic oncologists (Drs. De Vere White and Evans) to utilize metabolomics to tackle the problem of diagnosis and treatment of a cancer which is difficult to diagnose, whose incidence is increasing, and for which current treatment options are dismal. We are pleased that the reviewers agreed that the experiments in our proposal were sound. Successful completion of these experiments will result in a major advance in diagnosis as well as, ultimately, the selection of optimal treatment regimens for this disease. Ours will be the first described use of this technology in urologic malignancy, and one of the first to exploit this technology in any cancer. Furthermore, our work can serve as a model for using metabolomics to glean oncogenic pathway and network data from a variety of cancers.
Kidney cancer is the 6th most common cancer in the US. This disease, which often has no symptoms, is frequently diagnosed at a late stage when the prospects for cure are dismal. This project will set the stage to ultimately lead to a simple, office-based urine test for detection of kidney cancer, which can be utilized in the primary care clinic and which will lead to many lives being saved through early detection of this deadly cancer.
|Gupta, Romi; Dong, Yuying; Solomon, Peter D et al. (2014) Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A 111:E3062-71|
|Kim, Kyoungmi; Mall, Christine; Taylor, Sandra L et al. (2014) Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS One 9:e86223|
|Wecksler, Aaron T; Hwang, Sung Hee; Wettersten, Hiromi I et al. (2014) Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB. Anticancer Drugs 25:433-46|
|Zhang, Guodong; Panigrahy, Dipak; Hwang, Sung Hee et al. (2014) Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. Proc Natl Acad Sci U S A 111:11127-32|
|Ulu, Arzu; Harris, Todd R; Morisseau, Christophe et al. (2013) Anti-inflammatory effects of ?-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. J Cardiovasc Pharmacol 62:285-97|
|Wettersten, Hiromi I; Hee Hwang, Sung; Li, Cuiwen et al. (2013) A novel p21 attenuator which is structurally related to sorafenib. Cancer Biol Ther 14:278-85|
|Zhang, Guodong; Panigrahy, Dipak; Mahakian, Lisa M et al. (2013) Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110:6530-5|
|Wettersten, Hiromi I; Weiss, Robert H (2013) Applications of metabolomics for kidney disease research: from biomarkers to therapeutic targets. Organogenesis 9:11-8|
|Mall, Christine; Rocke, David M; Durbin-Johnson, Blythe et al. (2013) Stability of miRNA in human urine supports its biomarker potential. Biomark Med 7:623-31|
|Aboud, Omran Abu; Weiss, Robert H (2013) New opportunities from the cancer metabolome. Clin Chem 59:138-46|
Showing the most recent 10 out of 22 publications